Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
2019 was an average year for medtech M&A. 2020, not so much.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.